Wyeth’s Pristiq Best-Case Launch Scenario Targets Menopause Market
FDA is re-inspecting the manufacturing facility cited in an “approvable” letter for Wyeth’s initial NDA for major depressive disorder.
FDA is re-inspecting the manufacturing facility cited in an “approvable” letter for Wyeth’s initial NDA for major depressive disorder.